



Correction to: Caplacizumab: First Global Approval

Sean Duggan¹

Published online: 3 December 2018
© Springer Nature 2018

Correction to: Drugs (2018) 78(15):1639–1642
<https://doi.org/10.1007/s40265-018-0989-0>

The article Caplacizumab: First Global Approval, written by Sean Duggan, was originally published Online First without open access. After publication in volume 78, issue 15, pages 1639–1642 Ablynx NV requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Ablynx NV. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The original article has been corrected.

Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The original article can be found online at <https://doi.org/10.1007/s40265-018-0989-0>.

✉ Sean Duggan
dru@adis.com

¹ Springer, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand